Although SGLT-2 inhibitors are not FDA-approved for the treatment of MASLD, recent studies have shown promising results for the use of SGLT-2 inhibitors in patients with MASLD. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.